Lung cancer represents the most common cause of cancer-related death in the United States and accounts for nearly 13% of all new cancers.1,2 According to the American Cancer Society, approximately 228,150 new cases occurred in 2019 (116,440 in men and 111,710 in women) and 142,670 deaths resulted from lung cancer (76,650 in men and 66,020 in women).2
“Lung cancer kills more men and women in the United States than breast, prostate, and colon cancer combined,” David Tom Cooke, MD, FACS, associate professor, head of the Section of General Thoracic Surgery, and task force chair for the Comprehensive Lung Cancer Screening Program at UC Davis Health in Sacramento, California, told Pulmonology Advisor.2 The low survival rates in this patient population — 7% for small cell lung cancer and 21% for non-small cell lung cancer over 5 years — have been partially attributed to tumor identification at later stages of the disease, underscoring the need for early detection.1
Study findings have demonstrated a 5-year survival rate of 73% in patients with pathologic stage IA tumors compared with 36% and 9% in patients with stage IIB and IIIB tumors, respectively.1 However, an estimated “70% of lung cancer is diagnosed at more advanced stages, when the chance of cure is low,” said Dr Cooke.3
Since 2013, the Affordable Care Act has enabled greater access to lung cancer screening with low-dose computed tomography (LDCT) via required coverage by Medicare and private payors. The US Preventive Services Task Force (USPSTF) recommends annual screening for high-risk adults (aged 55-80 years with a 30 pack-year smoking history who currently smoke or have quit within the past 15 years), based on results of the National Lung Screening Trial (NLST) showing a 20% relative reduction in mortality with LDCT vs chest x-ray in patients with early-stage lung cancer.4
Despite recommendations, this resource remains underutilized, according to a study that analyzed 2016 data from all 1962 accredited radiographic screening sites.5 Only 2.0% of 7.6 million eligible smokers were screened that year, with rates ranging from 1.1% in the West to 3.9% in the Northeast. Although 40.4% of eligible smokers and 37.0% of accredited screening sites were located in the South, the screening rate in the region was among the lowest at only 1.7%. One key reason for these low screening rates is likely the dearth of screening centers, particularly in rural areas, despite higher rates of lung cancer death and smoking compared with metropolitan areas. A study published in the Annals of Thoracic Surgery found that there were 37 accredited LDCT facilities in Virginia, but only 2 were located in rural counties.6 “More screening centers are needed to care for the high number of rural smokers at risk for lung cancer,” the investigators concluded.
Substantial screening disparities have also been consistently noted among black Americans, the group with the highest rate of lung cancer mortality because of late diagnosis. In a 2018 study, researchers surveyed 200 randomly selected patients who were likely to meet USPSTF screening criteria.7 Only 21% of these individuals had been screened, and eligible non-black patients were nearly 3 times more likely to have been screened than eligible black patients (30% vs 12%).
“Targeted intervention strategies are needed to increase referral for and uptake of [lung cancer screening] in patients who are at high risk for developing lung cancer, and for black patients in particular,” stated the study authors.7